PMID- 34328090 OWN - NLM STAT- MEDLINE DCOM- 20211215 LR - 20211215 IS - 1950-6007 (Electronic) IS - 0753-3322 (Linking) VI - 141 DP - 2021 Sep TI - Kaempferia parviflora extract inhibits TNF-alpha-induced release of MCP-1 in ovarian cancer cells through the suppression of NF-kappaB signaling. PG - 111911 LID - S0753-3322(21)00693-4 [pii] LID - 10.1016/j.biopha.2021.111911 [doi] AB - Ovarian clear cell carcinoma (OCCC) is an uncommon subtype of epithelial cell ovarian cancers (EOCs) that has poor response to conventional platinum-based therapy. Therefore, finding new potential therapeutic agents is required. Since inflammatory cytokine, tumor necrosis factor alpha (TNF-alpha), is strongly expressed in EOCs and associated with the level of tumor grade, disruption of this inflammation pathway may provide another potential target for OCCC treatment. We previously reported that Kaempferia parviflora (KP) extract decreased cell proliferation and induced apoptosis. However, the effects of KP on OCCC, especially the aspects related to inflammatory cytokines, have not been elucidated. Our current study demonstrated the effects of KP extract on cytokine production in TNF-alpha-induced OCCC TOV-21G cell line. This study showed that KP extract inhibited interleukin 6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1) production at both transcription and translation levels via the suppression of nuclear factor-kappa B (NF-kappaB) signal transduction. In contrast, KP extract increased the expression of inhibitor kappa B (IkappaB) protein which may delay NF-kappaB translocation into the nucleus upon TNF-alpha activation. Moreover, the suppression of cytokines released from KP treated-TOV-21G reduced the migration of monocyte cell (THP-1). KP extract also exhibited the inhibition of IL-6 and MCP-1 production from THP-1 activated by lipopolysaccharides (LPS). Cells treated with KP extract exhibited a decrease in extracellular signal-regulated kinases (ERK1/2) and protein kinase B (AKT) phosphorylation and induced myeloid leukemia cell differentiation protein Mcl-1 (MCL-1) expression. Suppression of inflammatory cytokine and chemokine production and inhibition of tumor-associated macrophage (TAM) migration support the possibility of using KP for OCCC treatment. CI - Copyright (c) 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved. FAU - Thaklaewphan, Phatarawat AU - Thaklaewphan P AD - Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Graduate School, Chiang Mai University, Chiang Mai, Thailand. Electronic address: phatarawat.th@gmail.com. FAU - Ruttanapattanakul, Jirapak AU - Ruttanapattanakul J AD - Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. Electronic address: jirapak.ken@gmail.com. FAU - Monkaew, Sathit AU - Monkaew S AD - Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. Electronic address: sathit.monkaew@gmail.com. FAU - Buatoom, Montanee AU - Buatoom M AD - Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. Electronic address: montanee2535@gmail.com. FAU - Sookkhee, Siriwoot AU - Sookkhee S AD - Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. Electronic address: ssookkhee@hotmail.com. FAU - Nimlamool, Wutigri AU - Nimlamool W AD - Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Research Center of Pharmaceutical Nanotechnology, Chiang Mai University, Thailand. Electronic address: wutigri.nimlamool@cmu.ac.th. FAU - Potikanond, Saranyapin AU - Potikanond S AD - Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Research Center of Pharmaceutical Nanotechnology, Chiang Mai University, Thailand. Electronic address: saranyapin.p@cmu.ac.th. LA - eng PT - Journal Article DEP - 20210712 PL - France TA - Biomed Pharmacother JT - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie JID - 8213295 RN - 0 (CCL2 protein, human) RN - 0 (Chemokine CCL2) RN - 0 (NF-kappa B) RN - 0 (Plant Extracts) RN - 0 (Tumor Necrosis Factor-alpha) SB - IM MH - Cell Movement/drug effects/physiology MH - Cell Survival/drug effects/physiology MH - Chemokine CCL2/*metabolism MH - Dose-Response Relationship, Drug MH - Female MH - Humans MH - NF-kappa B/antagonists & inhibitors/*metabolism MH - Ovarian Neoplasms/drug therapy/*metabolism/pathology MH - Plant Extracts/isolation & purification/*pharmacology/therapeutic use MH - Tumor Necrosis Factor-alpha/antagonists & inhibitors/*toxicity MH - *Zingiberaceae OTO - NOTNLM OT - Kaempferia Parviflora OT - Monocyte chemotactic protein 1 OT - Ovarian carcinoma OT - Ovarian clear cell OT - Tumor necrosis factor-alpha EDAT- 2021/07/31 06:00 MHDA- 2021/12/16 06:00 CRDT- 2021/07/30 08:43 PHST- 2021/05/10 00:00 [received] PHST- 2021/06/29 00:00 [revised] PHST- 2021/07/06 00:00 [accepted] PHST- 2021/07/31 06:00 [pubmed] PHST- 2021/12/16 06:00 [medline] PHST- 2021/07/30 08:43 [entrez] AID - S0753-3322(21)00693-4 [pii] AID - 10.1016/j.biopha.2021.111911 [doi] PST - ppublish SO - Biomed Pharmacother. 2021 Sep;141:111911. doi: 10.1016/j.biopha.2021.111911. Epub 2021 Jul 12.